Cynthia Gonzalez
Family · McAllen, TXNPI 1902310287
Payments from drug & device makers
Across 105 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$285
- Otsuka America Pharmaceutical, Inc.$184
- Astellas Pharma US Inc$161
- Novartis$152
- AbbVie$145
- AstraZeneca$126
- plus $998 from 20 others
What the payments were for
- Food & beverage$1,95795%
- Education$945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $285 |
| Otsuka America Pharmaceutical, Inc. | 5 | $184 |
| Astellas Pharma US Inc | 5 | $161 |
| Novartis | 9 | $152 |
| AbbVie | 7 | $145 |
| AstraZeneca(2 entities) | 7 | $126 |
| GSK | 5 | $100 |
| Abbott | 2 | $100 |
| Johnson & Johnson | 5 | $95 |
| Lilly USA, LLC | 4 | $89 |
| Amarin Pharma, Inc. | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Biogen | 4 | $72 |
| Amgen | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Redhill Biopharma Inc. | 3 | $46 |
| Dexcom, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Eisai Inc. | 1 | $26 |
| Bayer | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,051 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 38 | $57,833 |
| OzempicSemaglutide | 36 | $45,137 |
| MounjaroTirzepatide | 18 | $27,078 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $26,944 |
| LinzessLinaclotide | 18 | $19,327 |
| TrintellixVortioxetine Hydrobromide | 12 | $16,318 |
| FarxigaDapagliflozin Propanediol | 12 | $13,423 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $13,267 |
| JardianceEmpagliflozin | 12 | $12,680 |
| XareltoRivaroxaban | 16 | $12,332 |
| VascepaIcosapent Ethyl | 12 | $9,812 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $8,058 |
| Ezetimibe | 56 | $3,617 |
| Omega-3 Acid Ethyl Esters | 18 | $2,610 |
| Aspirin-Dipyridamole ErAspirin/Dipyridamole | 11 | $1,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $89 | $84,91156 claims |
| Novo NordiskOzempic | $285 | $45,13736 claims |
| AbbVieLinzess | $145 | $19,32718 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $55 | $16,31812 claims |
| AstraZenecaFarxiga | $126 | $13,42312 claims |
| Boehringer IngelheimJardiance | $20 | $12,68012 claims |
| Johnson & JohnsonXarelto | $95 | $12,33216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in McAllen
- April LopezMcAllen$417K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.